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the original work isInternational tourism continues to increase worldwide, and people living with HIV and
their clinicians are increasingly confronted with the problem of how to dose antire-
troviral therapy during transmeridian air travel across time zones. No guidance on this
topic currently exists. This review is a response to requests from patient groups for clear,
practical and evidence-based guidance for travelling on antiretroviral therapy; we
present currently available data on the pharmacokinetic forgiveness and toxicity of
various antiretroviral regimens, and synthesize this data to provide guidelines on how to
safely dose antiretrovirals when travelling across time zones.
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medicineIntroduction
Combination antiretroviral therapy (cART) can provide
durable viral suppression of HIV infection and dramatic-
ally improve HIV-related mortality and morbidity [1].
High levels of adherence to therapy are necessary to
achieve optimal viral suppression and patients are
counselled against late dosing of their antiretrovirals in
order to prevent treatment failure [2] and development of
resistance [3]. Air travel across time zones can therefore
present challenges in the optimum timing of medication
administration, not only to minimize the chance of
developing resistant virus, but also to minimize the risk of
medication-related toxicity.
International tourism increased from 25 million inter-
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properly cited.in 2013 [4]. Patients on cART are among these,
benefitting from the improvement in survival and
wellbeing offered by effective therapy [5]. However, no
guidance on how to take medications when travelling
across time zones exists, and there seems to be a lack of
consistent advice from treating physicians, who, in our
experience, are less likely to regard this as a problem than
their patients. This review is a response to requests from
patient groups for clear, practical and evidence-based
guidance for travelling on cART.
It is essential to remember other vital considerations for
HIV positive travellers, including pretravel vaccination
and interaction of antiretrovirals with antimalarial
chemoprophylaxis. Full consideration of these aspects
of travel is beyond the scope of this review, but all HIV
positive travellers are advised discuss any travel plans withHospital, bWellcome Trust Liverpool Glasgow Centre for
European AIDS Treatment Group, Brussels, Belgium,
of Liverpool, Liverpool, and eSt Stephen’s Centre, Chelsea &
al and Infectious Diseases Unit, Royal Liverpool University
liverpool.ac.uk
: 28 September 2015.
ts reserved. This is an open access article distributed under the
se, distribution, and reproduction in any medium, provided
267
268 AIDS 2016, Vol 30 No 2their healthcare providers or a travel medicine specialist
well in advance of travel. It may be beneficial to obtain
contact details for local HIV support organizations at the
travel destination, which may be able to offer advice in
the event of unforeseen problems; online databases of
such organizations are available (e.g. www.aidsmap.com/
e-atlas).
Challenges of international travel with
combination antiretroviral therapy –
pharmacological and other considerations
Mammalian circadian rhythms are thought to be generated
by ‘pacemakers’ within the hypothalamic suprachiasmic
nuclei. Synchronization of the circadian rhythm to a 24-h
day requires regular exposure of these pacemakers to
environmental time clues, termed zeitgebers (time-givers),
such as daylight, sleep and food. In the absence of zeitgebers,
the human circadian rhythm graduates towards a 25-h
cycle. Jet lag disorder occurs when rapid transmeridian
travel causes circadian misalignment [6].
There are no data on the effect of transmeridian travel or
jet lag disorder on drug metabolism. Diurnal variation
in trough drug levels has been observed for some
antiretrovirals, including lopinavir [7], atazanavir [8] and
raltegravir [9] though no therapeutic relevance of this
phenomenon has been demonstrated for any drug [10].
Thus, the major impact of long distance travel remains
suboptimal dose spacing as a result of travelling (with
opportunistic pill intake), and following arrival in a new
time zone (where altered sleep patterns may impinge on
the next due dose). Individuals vary in medication intake
when travelling, ranging from missing multiple doses to
rigid timekeeping which requires pill taking at awkward
times.
Is it possible therefore to make recommendations for
medicine intake during travel which are pragmatic, safe
and evidence based? Pharmacokinetic data provide the
best guidance for forming recommendations through
understanding of the relationship between drug concen-
tration and therapeutic effect or toxicity, and estimation
of tolerance for late or early dosing around air travel. The
over-arching need is for pragmatic management, bearing
in mind the intended purpose of travel is to be productive
or pleasurable; any recommendations should not there-
fore act as a barrier to travel, especially as there are no
proven cases travel-induced erratic antiretroviral dosing
resulting in development of resistance and treatment
failure.
Clinical studies which have observed a pharmacokinetic–
pharmacodynamic relationship (e.g. efavirenz [11],
nevirapine [12], lopinavir [13], raltegravir [14]) have
defined antiretroviral minimum effective concentrations
(MEC). For other drugs, an in-vitro inhibitory concen-
tration (IC50/90/95) adjusted for protein binding (e.g.
darunavir [15], rilpivirine [16]) informs the dosingschedule. Nucleoside reverse transcriptase inhibitors
(NRTIs) require intracellular activation to active tripho-
sphate anabolites, the levels of which correlate poorly
with parent drug plasma levels; target levels of NRTIs
are therefore poorly defined [17]. The pharmacokinetic
forgiveness [18] is the time between the next due dose (at
which time the drug concentrations are at Cmin) and the
point at which the concentration of drug falls below the
estimated MEC. Knowledge of the forgiveness of a drug
therefore allows a clinician to advise a patient on how
long a dose may safely be delayed during travel.
Delayed dosing beyond the pharmacokinetic forgiveness
of a drug and subsequent subtherapeutic drug levels can
predispose to viral resistance and treatment failure.
However, early dosing may cause supratherapeutic drug
levels and toxicity. In addition, many antiretrovirals (e.g.
rilpivirine, efavirenz, tenofovir, elvitegravir and boosted
protease inhibitors) are ingested with specific recom-
mendations for food intake, which may be problematic
on commercial flights when meal times are fixed.
Characterizing the forgiveness of an
antiretroviral drug regimen: what data are
available?
The best data for estimating forgiveness of an anti-
retrovirals regimen derive from ‘tail’ studies tracking drug
elimination following treatment cessation in healthy
volunteers where median time to reaching MEC can be
calculated [19–23]. Where tail studies have not been
undertaken (e.g. nevirapine, etravirine, raltegravir,
maraviroc), an estimate of regimen forgiveness can be
extrapolated using average drug half-lives from standard
pharmacokinetic studies, though this is likely to be less
accurate. Indirect estimates of forgiveness can also be
derived from adherence and treatment interruption
studies. Here we consider the available data from each
of these sources in turn.
Tail data in healthy volunteers is available for boosted
atazanavir [19,20], boosted lopinavir once and twice daily
[20], boosted darunavir [19], co-formulated efavirenz/
tenofovir/emtricitabine [21], dolutegravir [22], co-
formulated elvitegravir/cobicistat/tenofovir/emtricita-
bine [22] and co-formulated rilpivirine/tenofovir/
emtricitabine [23] and is presented in Table 1. Although
MECs for NRTIs are not established, the pharmacoki-
netic parameters of the active intracellular metabolites of
tenofovir and emtricitabine have been established in one
tail study, where both were found to have long terminal
half-lives of 164 and 39 h, respectively [21]. This gives
some reassurance that regimens containing these long-
acting NRTIs provide a further element of forgiveness for
late dosing.
Tail data are not available for maraviroc, raltegravir,
nevirapine or etravirine. An estimation of pharmacoki-
netic forgiveness can bemade for these drugs from data on
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MECs [12,24–29].
Data from treatment interruption studies can also provide
an estimate of the forgiveness of a cART regimen.
The five-days-on two-days-off (FOTO) study assessed
the efficacy (in terms of virological suppression) of a
FOTO strategy for 30 HIV positive individuals on cART.
At 48 weeks 10/10 patients on efavirenz regimens were
virally suppressed, as were 8/9 patients of nevirapine-based
regimens, and 7/9 patients on protease inhibitor-based
(largely lopinavir-based) regimens [30]. This provides
some reassurance as to the forgiveness of these cART
agents.
Toxicity and genetic barrier to resistance
Significant toxic effects are unlikely for the majority of
antiretrovirals if a dose is taken a few hours early in the
context of international travel. Significant symptoms
from overdose of nevirapine have only been reported at
800mg or above [27]. Mild symptoms only were noted in
a massive lopinavir overdose of 270 Kaletra tablets [31].
Single doses of darunavir up to 3200mg and atazanavir up
to 1200mg have been administered to healthy volunteers
with no apparent ill effects [32,33]. Data on overdose of
etravirine, rilpivirine, raltegravir and elvitegravir are not
available but clinically important toxicity of these
antiretrovirals is uncommon [34].
Early dosing of efavirenz and maraviroc may be
problematic; increased efavirenz dose may enhance
neuropsychiatric toxicity [35], which is especially
undesirable at check-in. Maraviroc has been administered
up to 1200mg in clinical studies, and the dose limiting
effect is postural hypotension [24], which could also be
problematic whilst travelling.
The final important consideration in advising patients
how to alter the administration of cARTwhen crossing
time zones is the genetic barrier to resistance of their
medications. A low genetic barrier to resistance means
resistant virus may generate more rapidly when the level
of drug is below the MEC; efavirenz, nevirapine,
rilpivirine and raltegravir fall into this category;
maraviroc, etravirine and elvitegravir have a slightly
higher barrier to resistance, but still significantly lower
than the protease inhibitors and dolutegravir [36]. Any
functional antiretroviral monotherapy causes increased
risk of generating viral resistance; this is of potential
concern with late dosing of protease inhibitors when they
are used as monotherapy, but also in the late dosing of
cART when individual components of a regimen have
different half-lives.
Advice for travellers
There are two potential issues to tackle with regard to
time of dosing; firstly, how and when to dose during a
long distance flight across time zones; and secondly, how
270 AIDS 2016, Vol 30 No 2
Table 2. Recommendations for antiretroviral intake for transmeridian travel more than 8h.
Drug Dosing recommendation for travel
Likely to be tolerant of late dosing Tenofovir, emtricitabine, lamivudine,
abacavir, didanosine
OD dosing – adjust intake to dose before travel,
and after arrival. For efavirenz, dosing
immediately prior to departure should be
avoided – instead dosing can be safely
stretched from previous evening (from FOTO
data)
Efavirenz OD BD dosing – adjust intake to dose before
departure (for flights of 12 h or less), or take an
extra dose in-flight at a convenient time for
longer duration flights. Take next dose after
arrival
Nevirapine OD or BD All subsequent dosing according to new time
zone
Rilpivirine OD
Boosted atazanavira OD
Boosted darunavira OD or BD
Boosted elvitegravira OD
Dolutegravir OD or BD
Maraviroc ODa or BD
Likely to be moderately tolerant
of late dosing
Stavudine, zidovudine lopinavir/ritonavir BID As above for BD dosing. All subsequent dosing
according to new time zone
Raltegravir BD
Darunavir/ritonavir monotherapy
Likely to be poorly tolerant of
late dosing
Lopinavir/ritonavir OD Take an extra dose in-flight. All subsequent dosing
according to new time zone
Unboosted atazanavir
Monotherapy with boosted atazanavir or
lopinavir
BD, twice daily; FOTO, five-days-on, two-days-off; OD, once-daily.
aBoosted with ritonavir or cobicistat.to shift the medication regimen to a new time zone. The
longest recorded commercial flight is just under 19 h from
Newark to Singapore [37]. Using this longest possible
flight time, we suggest general principles to guide patients
taking cARTwhen crossing time zones.1. The risk of travel is lowest when the patient is stable on
their cARTwith a well suppressed viral load; for indivi-
duals whose viral load is unsuppressed a careful risk assess-
ment on a case-by-case basis should be carried out, and the
following recommendations may not be appropriate.2. Many travellers have already established a system for
taking their medication whilst travelling; if this is
successful without evidence of virological rebound, it
can be safely continued.3. Due to confusion regarding times and fixed mealtimes,
we recommend avoidance of in-flight dosing if possible
and safe to do so.4. Although in-flight dosing can be avoided for many
regimens, the MECs for patients with known resistant
virus are likely to be higher and consideration should be
given to dosing in-flight.5. In addition, complex itineraries with multiple time zone
shifts in the space of a few days may require more careful
planning and may require in-flight dosing.6. Get into the new time zone as quickly as possible; dosing
according to country of origin is likely to result in
confusion and poor adherence. Compensate with an
extra dose on arrival if necessary.Using these general principles and data on the forgiveness
of different antiretrovirals, we suggest specific dosing
recommendations by antiretroviral for transmeridian
travel more than 8 h (Table 2).Conclusion
Pharmacokinetic data to guide clinicians and their
patients in dosing antiretrovirals when crossing time
zones are incomplete; nevertheless, this review sum-
marizes and interprets existing data, offering a
framework for safe administration. Clinicians should
not neglect the other aspects of a pretravel consultation
for the HIV positive traveller, who should be
encouraged to ensure they have an adequate supply
of tablets, consider pretravel vaccinations and malarial
chemoprophylaxis when necessary, along with a
standard assessment of the risks of travel to any
destination. The pharmacokinetic profile and side-
effect profile of the majority of the reviewed
antiretrovirals, in conjunction with the fact that there
are no proven case reports of travel-induced erratic
dosing of antiretrovirals bringing about treatment
failure should reassure people living with HIV and
their physicians that transmeridian travel across time
zones can be safe, and enjoyable.
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